Skip to main content

Table 2 Treatment, relapsing, disease status, death neoplasia and follow up of patients with dermatomyositis

From: Frequency and clinical relevance of anti-Mi-2 autoantibody in adult Brazilian patients with dermatomyositis

  Total
(n = 87)
Mi-2 (+)
(n = 17)
Mi-2 (−)
(n = 70)
P value
Treatment
 Methylprednisolone pulse therapy 37 (42.5) 10 (58.8) 27 (38.6) 0.173
 IVIG pulse therapy 24 (27.6) 7 (41.2) 17 (24.3) 0.225
 Rituximab 15 (17.2) 4 (23.5) 11 (15.7) 1.000
 Prednisone
  Current use 27 (31.0) 2 (11.8) 25 (35.7) 0.079
  Current dose (mg/day) 0 [0–5] 0 [0–0] 0 [0–10] 0.042
 Immunosuppressive drugs
  Current use 49 (56.3) 7 (41.2) 42 (60.0) 0.182
Disease relapsing 17 (19.5) 3 (17.6) 14 (20.0) 1.000
Current disease status
 Disease remission 29 (33.3) 10 (58.8) 19 (27.1) 0.021
 Complete clinical response 49 (56.3) 6 (35.3) 43 (61.4) 0.062
 Disease activity 9 (10.3) 1 (5.9) 8 (11.4) 0.682
Death 12 (13.8) 2 (11.8) 10 (14.3) 1.000
Neoplasia 4 (4.6) 2 (11.8) 2 (2.9) 0.170
Follow-up 38 (43.7) 5 (29.4) 33 (47.1) 0.279
  1. IVIG Intravenous human immunoglobulin